Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799389 | 0.91 | NPC1 (0.36) | CA1CA2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1358620 | 0.89 | KDM4E (0.33) | CA1CA2MIFTP53MAPT | |
| SCHEMBL14728013 | 0.88 | CA1 (0.34) | CA1CA2MIFTP53MAPT | |
| SCHEMBL14727965 | 0.88 | ACLY (0.35) | CA1CA2 | |
| SCHEMBL1798784 | 0.87 | GPR52 (0.35) | CA1CA2 | |
| SCHEMBL1466992 | 0.84 | PDK2 (0.34) | CA1CA2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1801804 | 0.84 | PDK2 (0.34) | CA1CA2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2011937 | 0.83 | RXRA (0.35) | CA1CA2MIFRXRANR1H2 | |
| SCHEMBL2015760 | 0.83 | CA1 (0.32) | CA1CA2MIF | |
| SCHEMBL12846412 | 0.83 | PTGES (0.34) | CA1CA2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748155-B1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-9247740-B2 | Isoxazoline derivatives as insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-9247740-B2 | Isoxazoline derivatives as insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-20140206606-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20140206606-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| WO-2013026695-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026931-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206606-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | CHRM1, CHRM3, CHRM2 | CA1 1012/4885CA2 380/4885MIF 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.